Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Real-time Estimate Cboe BZX
Other stock markets
 01:10:10 2024-04-23 pm EDT 		5-day change 1st Jan Change
24.68 USD +2.11% Intraday chart for Mirum Pharmaceuticals, Inc. +3.04% -16.19%
Apr. 17 Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target MT
Apr. 02 Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LIVMARLI (solution orale de maralixibat) de Mirum Pharmaceuticals reçoit une recommandation de remboursement positive de l’ACMTS du Canada pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Sector Update: Health Care
US FDA approves expanded use of Mirum's liver disease drug
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Mirum Pharmaceuticals, Inc. Announces Management Changes
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer
Mirum Pharmaceuticals, Inc. Announces Management Appointments
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023
Sector Update: Health Care Stocks Rise in Late Afternoon
Sector Update: Health Care Stocks Rising Monday Afternoon
Mirum Pharmaceuticals Shares Fall After Disappointing Data From Phase 2B Study for Biliary Atresia
Mirum Pharma's liver disease therapy fails in mid-stage study
Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia
LIVMARLI (maralixibat) di Mirum Pharmaceutical è stato ammesso al rimborso ed è ora disponibile in Italia per il trattamento del prurito colestatico in pazienti affetti da sindrome di Alagille
Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.
  5. Other languages